Topical PDGF-BB results in limited healing in a patient with Werner’s syndrome and chronic leg ulcers

Wollina, Uwe; Gruner, Monika; Koch, Andrè; Köstler, E; Hubl, W; Nb, Hanson; Oshima, Junko

doi:10.12968/jowc.2004.13.10.26690

Cited by 14 publications

(10 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only one drug, recombinant human PDGF‐BB (becaplermin [Regranex]; Healthpoint, Ft. Worth, TX, USA), has obtained Food and Drug Administration approval for a chronic wound treatment indication in the past 20 years . However, topical PDGF‐BB results in limited healing of leg ulcers in Werner syndrome patients . In a case report, Bosentan, an endothelin receptor agonist, was reported to be effective for the treatment of severe skin ulcers in Werner syndrome patients .…”

Section: Discussionmentioning

confidence: 99%

“…One patient with Werner syndrome was in the 0.1% SR‐0379 treatment group and showed a 34.92% size reduction, and another patient was in the 0.02% SR‐0379 treatment group and showed a 61.45% size reduction. Because ulcers associated with Werner syndrome are reported to be drug‐resistant, in the current study the potential effects of SR‐0379 on leg ulcers of patients with Werner syndrome were evaluated in comparison with the effects of SR‐0379 on diabetic ulcers …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Investigator‐initiated clinical study of a functional peptide, SR‐0379, for limb ulcers of patients with Werner syndrome as a pilot study

Nakagami

Sugimoto

Ishikawa

et al. 2019

Geriatrics Gerontology Int

View full text Add to dashboard Cite

Aim An investigator‐initiated clinical study was carried out to evaluate the therapeutic potency of SR‐0379 for the treatment of leg ulcers in patients with Werner syndrome. Methods A multicenter, open‐label study was carried out from September 2017 to February 2018. The inclusion criteria for leg ulcers were: (i) leg ulcers in patients with Werner syndrome, diabetes or critical limb ischemia/venous stasis; and (ii) a wound size of >1 cm and <6 cm in diameter. Four individuals with Werner syndrome and diabetic ulcers, respectively, were enrolled. SR‐0379 (0.1%) was sprayed on skin ulcers once per day for 4 weeks. Efficacy was evaluated by determining the rate of wound size reduction as a primary end‐point at 4 weeks after the first treatment compared with the pretreatment wound size. As secondary end‐points, the DESIGN‐R score index, the 50% wound size reduction ratio, time to wound closure and quantification of wound bacteria were also evaluated. The safety of SR‐0379 was evaluated during the study period. Results The reduction rate of ulcer size treated with 0.1% SR‐0379 was 22.90% (mean) in the Werner syndrome ulcers group (n = 4) and 35.70% (mean) in the diabetic ulcers group (n = 4), respectively. The DESIGN‐R score decreased by 4.0 points in the Werner syndrome ulcers group and 4.3 points in the diabetic ulcers group. Two mild adverse events were reported in two patients, and causal relationships were denied in any events. Conclusion Treatment with SR‐0379 was safe, well‐tolerated, and effective for leg ulcers of both Werner syndrome and diabetes patients. Geriatr Gerontol Int 2019; 19: 1118–1123.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Investigator‐initiated clinical study of a functional peptide, SR‐0379, for limb ulcers of patients with Werner syndrome as a pilot study

Nakagami

Sugimoto

Ishikawa

et al. 2019

Geriatrics Gerontology Int

View full text Add to dashboard Cite

show abstract

“…The more recent studies in which cataract surgery was done by phacoemulsification show that it can be done safely without an increased rate of complications. [5] In this patient, cataract surgery was done by phacoemulsification with the following precautions: (1) small incision size of 2.8 mm; (2) liberal use of sodium hyaluronate 1.4% to protect the corneal endothelium; (3) closure of the corneal tunnel and side ports using 10/0 nylon suture to prevent wound dehiscence (impaired wound healing is a feature of WS);[6] (4) weak steroids were used postoperatively so as not to suppress fibroblast proliferation. Decreased fibroblast proliferation rate has been proved by cell culture in WS[2] and could be the cause for impaired wound healing.…”

Section: Discussionmentioning

confidence: 99%

Endothelial cell study in a case of Werner′s syndrome undergoing phacoemulsification and Yettrium-Aluminum-Garnet laser capsulotomy

Kemmanu

Hegde

Yadav

et al. 2012

Indian J Ophthalmol

View full text Add to dashboard Cite

Werner's syndrome (WS) is a rare autosomal recessive disorder with multisystem manifestations of premature aging from the second decade of life. Cataract is one of the features of WS. Cataract surgery is complicated with postoperative wound dehiscence and bullous keratopathy when the surgery is done by intracapsular or conventional extracapsular method. We report the short-term result of phacoemulsification and Neodymimum Yettrium-Aluminum-Garnet laser (Nd YAG) capsulotomy in a case of WS with bilateral cataracts. Postoperatively and post capsulotomy, there was no change in the endothelial cell morphology. There was an 8.6% decrease in endothelial cell count at the end of 15 months postoperatively and 11 months post YAG capsulotomy. This decrease is within the acceptable range of cell loss after phacoemulsification and YAG capsulotomy. To the best of our knowledge, this is the first reported case of YAG laser capsulotomy in WS.

show abstract

“…PDGF is the most researched of all the growth factors, and was originally studied in the management of pressure ulcers [58,63,65], and was eventually approved in North America for the treatment of diabetic lower extremity ulcers [66,67]. PDGF promotes chemotaxis of neutrophils, monocytes and smooth muscle cells in wounds.…”

Section: Platelet Derived Growth Factormentioning

confidence: 99%

Techniques for Wound Healing with a Focus on Pressure Ulcers Elimination

Kuffler¹

2012

TOCVJ

View full text Add to dashboard Cite

Pressure ulcers, also called decubitus ulcers, are a common challenge of humanity. They are wounds initiated by pressure on the skin that blocks circulation causing the skin and underlying tissues to die. Without care, pressure ulcers continue to grow in diameter and depth and are exceptionally difficult to heal. They have probably always existed, and are present on Egyptian mummies. Pressure ulcers are a serious health issue, very painful, a significant physiological challenge, can shorten the life of a patient, are an emotional and financial burden to the patient, those who deal with them, and in the United States alone annually costs in excess over $10 billion dollars for care and prolonged hospitalization. Pressure ulcers can develop with as little as two hours of pressure, and because even a brief lapse in avoidance of pressure leads to ulcers, they are frequently impossible to prevent, even for the most conscientious patient with an extensive support group and unlimited financial resources. Therefore, enormous effort is required to find effective and reliable techniques for preventing the initiation of ulcers and eliminating them once they develop. This review looks at the various approaches presently used and in development for the treatment of pressure ulcers, evaluates which may be best in eliminating ulcers, and discusses combinations of techniques that may be most effective in eliminating pressure ulcers.

show abstract

Topical PDGF-BB results in limited healing in a patient with Werner’s syndrome and chronic leg ulcers

Abstract: Impaired wound healing is a feature of Werner's syndrome. Treatment of one such patient with painful chronic leg ulcers included topical application of PDGF-BB. Granulation increased slightly, enabling full-thickness skin grafting to take place.

Cited by 14 publications

References 14 publications

Investigator‐initiated clinical study of a functional peptide, SR‐0379, for limb ulcers of patients with Werner syndrome as a pilot study

Investigator‐initiated clinical study of a functional peptide, SR‐0379, for limb ulcers of patients with Werner syndrome as a pilot study

Endothelial cell study in a case of Werner′s syndrome undergoing phacoemulsification and Yettrium-Aluminum-Garnet laser capsulotomy

Techniques for Wound Healing with a Focus on Pressure Ulcers Elimination

Contact Info

Product

Resources

About